We have a number of ongoing research studies for children with diabetes. Descriptions follow.
Type 1 Diabetes Exchange Registry
The Type 1 Diabetes (T1D) Exchange is designed to gather data for patients with type 1 diabetes. The exchange aims to have 100,000 members and a network of over 60 clinical centers within 3 years. The primary goal of the T1D Program is to advance the understanding of type 1 diabetes and to identify promising new treatments, technologies and solutions for patients. Participating individuals will complete questionnaires that include diabetes care, insulin management, and family history yearly at clinic appointments. A $20 amazon.com gift certificate will be provided after the initial enrollment. To be eligible you must:
1. Have type 1 diabetes
2. Currently be using insulin to manage your diabetes
3. Age range of birth to 99 years old
For more information, contact the Principal Investigator; Linda DiMeglio, MD or Stephanie Woerner, FNP at 317-944-2573.
Immune Tolerance Network T1DAL Study for Persons with New-Onset Type 1 Diabetes
The study is sponsored by the Immune Tolerance Network (ITN), an NIH-funded multi-center national consortium dedicated to conducting new-onset studies in children and adults recently diagnosed with Type 1 diabetes
The T1Dal study is an intervention study for people with newly diagnosed type 1 diabetes. The study is being conducted to determine if weekly injections of alefacept (Amevive®), an investigational medication, will help people continue to make some of their own insulin. Studies have shown that people who continue to make insulin have less trouble with low blood sugars and fewer complications from their diabetes than people who no longer make any insulin. This research study will compare people who get the investigational treatment with those who do not.
We are currently enrolling eligible candidates that meet the following criteria:
• 12 to 35 years of age.
• Diagnosed with type 1 diabetes fewer than 3 months ago
For More Information Contact Linda DiMeglio, MD, MPH at 948-8879 or Jennifer Terrell at 274-2584
Type 1 Diabetes TrialNet
TrialNet is conducting three types of research:
1. Pathway to Prevention Studies: to learn more about risk factors associated with the development of type 1 diabetes. Looking for family members of personswith Type 1 Diabetes. Currently accepting new participants.
2. Diabetes Prevention Studies: to test therapies that may delay or prevent the onset of type 1 diabetes. Currently accepting new participants.
3. Diabetes Intervention Studies: to test therapies that may preserve insulin secretion in people recently diagnosed with type 1 diabetes. Call for information.
See separate flyer for more information and business cards.
For more information contact the Principal Investigator; Linda DiMeglio, MD, MPH or Maria Nicholson, RN at 1-866-230-8486 or 317-948-8879 or go to https://www.diabetestrialnet.org.
Long Term Insulin Pump Therapy in Very Young Children with Diabetes
1. Investigations of clinical, brain function, behavioral, academic achievement, and quality of life measures in 20 children aged 6-10 years diagnosed with diabetes for > 5 years who have received long-term insulin pump therapy (> 3 years) compared to children matched for age, sex, average blood sugars, and diabetes duration treated with insulin injections.
2. Assessments of blood sugar outcomes, cognitive outcomes, parenting stress, and diet changes in 40 children with diabetes under 5 years of age prior to and 12 months after the implementation of insulin pump therapy.
3. Analysis of our clinic population utilizing pumps, collecting outcome data on: clinical variables, predictors of long-term 'success' in blood sugar control, quality of life, and autonomy in diabetes management.
For more information contact the Principal Investigator; Linda DiMeglio, MD or the Study Coordinator; Stephanie Woerner, FNP at 317-944-2573
Studies to Treat or Prevent Pediatric Type 2 diabetes: TODAY Genetics Study
The TODAY genetics study is funded by the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) with the primary goal to collect blood and phenotypic information to explore relationships between certain genes and Type 2 DM, obesity, insulin resistance and cardiovascular complications of insulin resistance. More than 30 diabetes centers across the U.S. including Riley Hospital are participating in the TODAY genetic study, with a goal of enrolling 2500 individuals.
1. All individuals who are diagnosed with Type 2 diabetes before 18 years of age are eligible
2. When a person joins the study, he/she (or a caregiver) completes a form with questions about diabetes and family history and the study team collects information about his/her diabetes that is recorded in the medical chart. In addition after completing the forms the study team will draw 2 tablespoons of blood to be sent for testing. Persons who complete the study receive a small honorarium ($25).
For more information contact the Principal Investigator; Zeina Nabhan, MD, MS or the study coordinator Paula Didrick, at 317-944-3889.